➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Boehringer Ingelheim
Johnson and Johnson
Merck
Moodys

Last Updated: March 2, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Aminopterin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Aminopterin?

Aminopterin is an investigational drug.

There have been 106 clinical trials for Aminopterin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2001.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Lymphoid, and Precursor Cell Lymphoblastic Leukemia-Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Children's Oncology Group, and Fred Hutchinson Cancer Research Center.

Recent Clinical Trials for Aminopterin
TitleSponsorPhase
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaM.D. Anderson Cancer CenterPhase 1/Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerNational Cancer Institute (NCI)Phase 3
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)National Cancer Institute (NCI)Phase 2

See all Aminopterin clinical trials

Clinical Trial Summary for Aminopterin

Top disease conditions for Aminopterin
Top clinical trial sponsors for Aminopterin

See all Aminopterin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Boehringer Ingelheim
Johnson and Johnson
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.